Schaeffer's Top Stock Picks for '25

Analysts Chime In on Big Pharma Ahead of Earnings

PFE said it would delay raising drug prices after a Trump tweet

Jul 11, 2018 at 10:51 AM
facebook X logo linkedin


Analysts are weighing in on big pharma today, with AbbVie Inc (NYSE:ABBV) and Pfizer Inc. (NYSE:PFE) among the names in the spotlight. Attention for the former is more upbeat, while notes for the latter are tilted toward the skeptical side -- even after both stocks' recent run up the charts.

Diving deeper, J.P. Morgan Securities said strong quarterly earnings results for drug companies will likely be offset the recent strength in the U.S. dollar. The brokerage firm believes Pfizer will be among those most negatively impacted by forex issues, while Abbvie -- and Eli Lilly (LLY) -- will see a more modest headwinds.

Elsewhere, SunTrust Robinson expressed concern over Pfizer's announcement that it will delay hiking drug prices for up to six months, after its CEO talked to President Donald Trump following a scathing POTUS tweet. The brokerage firm maintained its "hold" rating on PFE stock, while saying to accumulate shares of ABBV -- which it rates a "buy" -- given the latter's volume-driven sales growth on new products.

At last check, PFE was trading down 0.5% at $37.23, with traders also reacting to news the big-cap pharma name plans to split into three companies in order to separate its consumer healthcare business, which it's been trying to sell since 2017. More broadly, the shares have been swinging higher since their early May lows, up 8.4%.

ABBV, meanwhile, has plunged 2.5% today to trade at $96.35. News the company's cancer drug, Imbruvica, failed in a late-stage study is offsetting the upbeat analyst attention, with the shares on track to snap their eight-day win streak -- their longest since March 2017. Nevertheless, the drug stock is still churning below its 200-day moving average, which has kept a tight lid on the equity since mid-June.

 
 

Which of These SUB-$5 Stocks Could 26x From Here? (AD)

He called a rare 11x on Tesla…

Then he called a 26x on Workhorse…

Then an even rarer 35x on Nio Inc…

Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.

They’re trading for less than $5 right now.

But thanks to Elon & Trump’s new alliance…

They could be off to the races in Trump’s first 100 days.

And right now for a limited time…

You can get the names & tickers for just $1 here. (AD)

10 Stock Picks FREE
 
 

Featured Articles from Trusted Partners:

🚀 One Stock Pick Could Change Everything in 2025
What if one stock pick could define your success next year? Get 10 expert-vetted stocks set for 2025—plus 5 bonus picks to watch now. Get the Report →

🆕 New Options Need New Trading Strategies
Zero-DTE options are the newest (and hottest) options to trade.  Professional traders have rushed into the market and are making a mint.  Don’t get left behind - learn all about these options, how to trade them, market setups to profit from, plus much more. Download now →

👀 Revealed: 3 Defensive Stocks for Your Portfolio
Worried about the market? This free report reveals 3 under-the-radar defensive stocks for uncertain times in any kind of economy.

 

 
 

FREE Report Download

 

Follow us on X, Follow us on Twitter